Mazor Robotics Signs Agreement with Leading Group Purchasing Organization (GPO)

CAESAREA, Israel – January 14, 2014 – Mazor Robotics Ltd. (NASDAQCM: MZOR; TASE: MZOR), the developer of Renaissance®, an innovative surgical guidance system and its complementary products, announced that it has signed an agreement with one of the largest group purchasing organizations (GPO) for hospitals, as well as acute and non-acute healthcare facilities.  Under the agreement, the Company’s Renaissance system and portfolio of disposable products will be available to the members of one of the largest hospital corporations in the U.S with hundreds of hospitals and freestanding surgery centers. Three of the member hospitals under this GPO have previously purchased Renaissance and are currently utilizing the system.

“This is a significant achievement putting in place a framework to expand our Renaissance footprint with this hospital corporation,” commented Ori Hadomi, Mazor’s Chief Executive Officer. “With three of its member hospitals already using the Renaissance system, it clearly demonstrates the effectiveness of our strategy to penetrate individual hospitals as well as national accounts.”

As the only FDA cleared surgical guidance technology for spine surgery available in the marketplace, surgeons and administrators in the U.S and internationally are benefitting from the positive clinical and business aspects of the system.

About Mazor

Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary robotic-based technology and products aimed at redefining the gold standard of quality care. Mazor Robotics Renaissance® Guidance System enables surgeons to conduct spine and brain procedures in a more accurate and secure manner. For more information, please visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the expectations for growth in system sales and recurring revenue, the Company’s expected sales in 2016, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC) including those discussed under the heading “Risk Factors” in Mazor’s annual report on Form 20-F filed with the SEC on April 29, 2015 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.

U.S. Contacts: EVC Group

Michael Polyviou/Doug Sherk – Investors

212.850.6020; 646-445-4800

David Schemelia – Media


Latest Tweet

Mazor #CoreTechnology can help you produce consistent results that lead to improved clinical outcomes. Get more inf…
Follow Mazor Robotics on Twitter
©2018 Mazor Robotics. All Rights Reserved. Designed By Medtech Momentum